#United States #Fort Lauderdale #Biopharmaceutical #GBI Biomanufacturing #Jesse McCool

GBI Biomanufacturing Welcomes New Leadership

In a significant move for the biopharmaceutical landscape, GBI Biomanufacturing has announced the appointment of Jesse McCool, Ph.D., as its new President. This announcement, made on January 6, 2026, comes as GBI looks to bolster its integrated services and drive innovation within the biologics Contract Development and Manufacturing Organization (CDMO) sector.

A Wealth of Experience

Dr. McCool joins GBI with over twenty years of experience in the biopharmaceutical field, bringing a rich background that includes leadership roles at prominent organizations such as Lonza Group, Wheeler Bio, and Cytovance Biologics. His extensive experience spans various domains including process development, GMP manufacturing, and advanced therapies, particularly noting his expertise in microbial and mammalian production platforms. This breadth of knowledge positions him well to lead GBI into its next phase of growth.

Kaul Pinto, Chairman of the Board at GBI Biomanufacturing, expressed excitement over Dr. McCool's appointment, highlighting his respected status within the industry: "Jesse is a respected executive within the biologics CDMO industry, and he brings with him a wealth of experience across numerous organizations. His passion for biologics and commitment to customer experience will ensure that GBI continues its momentum during our ongoing expansion efforts."

Fostering Innovation and Growth

In his inaugural remarks as President, Dr. McCool stated, "I'm passionate about transforming scientific innovation into real-world impact. To advance that mission, I have spent my career innovating and operating in the biologics CDMO industry. I am thrilled to join Karl and his world-class team in the Miami metro and continue to drive forward a new, exciting growth phase for GBI." His vision focuses on leveraging GBI’s robust capabilities to support biopharma innovators, reducing development and manufacturing risks while enhancing customer satisfaction.

As President, Dr. McCool plans to strengthen GBI's integrated CDMO offerings. This includes expanding services in process development, analytical support, cGMP drug substance manufacturing, and aseptic fill-finish capabilities. The company is also noted for its specialized abilities in managing complex biologics, including conjugated modalities, while maintaining rigorous quality systems for effective clinical and commercial execution.

Continued Commitment to Biopharma Innovation

Under Dr. McCool’s leadership, GBI is well-positioned to continue its emphasis on collaboration with biotechnology and pharmaceutical companies. The organization aims to ensure compliance and efficiency in progressing complex biologic programs from early development phases all the way through to commercial supply. GBI's commitment to innovation arises from its goal of not just meeting but exceeding the expectations of its clients in an evolving market.

In summary, the addition of Dr. Jesse McCool as President marks a strategic step for GBI Biomanufacturing. With a track record of leadership and innovation, Dr. McCool is expected to guide the company into a promising future in the biopharmaceutical arena. For more information regarding GBI’s offerings and capabilities, visit their official website at www.gbibio.com.

About GBI Biomanufacturing

GBI Biomanufacturing specializes in providing integrated services across biologics development and cGMP manufacturing, partnering with clients to navigate the complexities of biopharmaceutical production efficiently and compliantly.